Temsirolimus
- Generic Name
- Temsirolimus
- Brand Names
- Torisel
- Drug Type
- Small Molecule
- Chemical Formula
- C56H87NO16
- CAS Number
- 162635-04-3
- Unique Ingredient Identifier
- 624KN6GM2T
- Background
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
- Indication
For the treatment of renal cell carcinoma (RCC). Also investigated for use/treatment in breast cancer, lymphoma (unspecified), rheumatoid arthritis, and multiple myeloma.
- Associated Conditions
- Advanced Renal Cell Carcinoma
Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
- Conditions
- Alveolar RhabdomyosarcomaBotryoid-Type Embryonal RhabdomyosarcomaEmbryonal RhabdomyosarcomaSclerosing RhabdomyosarcomaRhabdomyosarcomaSpindle Cell Rhabdomyosarcoma
- Interventions
- Other: Laboratory Biomarker AnalysisOther: Questionnaire AdministrationRadiation: Radiation Therapy
- First Posted Date
- 2015-10-05
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 325
- Registration Number
- NCT02567435
- Locations
- 🇺🇸
Saint Mary's Medical Center, West Palm Beach, Florida, United States
🇺🇸Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸USA Health Strada Patient Care Center, Mobile, Alabama, United States
Personalized Targeted Inhibitors Treatment in Renal Cell Cancer
- Conditions
- Carcinoma, Renal Cell
- Interventions
- First Posted Date
- 2015-09-25
- Last Posted Date
- 2018-10-12
- Target Recruit Count
- 4
- Registration Number
- NCT02560012
- Locations
- 🇺🇸
UTHealth Memorial Hermann Cancer Center, Houston, Texas, United States
Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence
- Conditions
- Solid Tumor
- Interventions
- First Posted Date
- 2015-05-18
- Last Posted Date
- 2015-05-18
- Lead Sponsor
- Miller Children's & Women's Hospital Long Beach
- Target Recruit Count
- 20
- Registration Number
- NCT02446431
- Locations
- 🇺🇸
Miller Children's and Women's Hospital Long Beach, Long Beach, California, United States
🇺🇸Children's Hospital Orange County, Orange, California, United States
Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)
- Conditions
- Colorectal CarcinomaAdvanced CancerPancreatic CancerRenal Cell CancerUterineNon Small Cell Lung CancerEndometrial
- Interventions
- First Posted Date
- 2015-04-22
- Last Posted Date
- 2018-07-02
- Lead Sponsor
- Western Regional Medical Center
- Target Recruit Count
- 33
- Registration Number
- NCT02423954
- Locations
- 🇺🇸
Cancer Treatment Center of America @ Western Regional Medical Center, Goodyear, Arizona, United States
Vorinostat and Temsirolimus With or Without Radiation Therapy in Treating Younger Patients With Newly Diagnosed or Progressive Diffuse Intrinsic Pontine Glioma
- Conditions
- Diffuse Intrinsic Pontine Glioma
- Interventions
- First Posted Date
- 2015-04-20
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT02420613
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid Tumors
- Conditions
- Recurrent Malignant Solid NeoplasmAdvanced Malignant Solid NeoplasmRefractory Brain NeoplasmRecurrent Brain Neoplasm
- Interventions
- First Posted Date
- 2015-03-17
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 14
- Registration Number
- NCT02389309
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Vinblastine and Temsirolimus in Pediatrics With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours
- Conditions
- Recurrent LymphomaRefractory LymphomaSolid TumoursCentral Nervous System
- Interventions
- First Posted Date
- 2015-01-22
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- Canadian Cancer Trials Group
- Target Recruit Count
- 7
- Registration Number
- NCT02343718
- Locations
- 🇨🇦
Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada
🇨🇦CHU Sainte-Justine, Montreal, Quebec, Canada
🇨🇦Hospital for Sick Children, Toronto, Ontario, Canada
Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas
- Conditions
- Anaplastic AstrocytomaGlioblastomaAnaplastic OligodendrogliomaMixed GliomaBrain Tumor, Recurrent
- Interventions
- First Posted Date
- 2014-09-12
- Last Posted Date
- 2023-05-25
- Lead Sponsor
- Andrew B Lassman, MD
- Target Recruit Count
- 10
- Registration Number
- NCT02238496
- Locations
- 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Temsirolimus and Cetuximab in Patients With Advanced or Metastatic Solid Tumors
- Conditions
- Patients With Advanced or Metastatic Solid Tumors
- Interventions
- First Posted Date
- 2014-08-13
- Last Posted Date
- 2016-02-10
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 42
- Registration Number
- NCT02215720
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, Val de Marne, France
POEM STUDY: A Phase IIa Trial in Endometrial Carcinoma With Temsirolimus
- First Posted Date
- 2014-03-21
- Last Posted Date
- 2020-11-27
- Lead Sponsor
- MedSIR
- Target Recruit Count
- 10
- Registration Number
- NCT02093598
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.